Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-28T11:21:42.430Z Has data issue: false hasContentIssue false
  • English
  • Français

Novel Approaches to Controlled-Release Antigen Delivery

Published online by Cambridge University Press:  14 October 2009

Smadar Cohen ,
Maria J. Alonso  and
Robert Langer
Smadar Cohen
Affiliation:
Ben Gurion University of the Negev, Israel
Maria J. Alonso
Affiliation:
School of Pharmacy, Santiago de Compostela, Spain
Robert Langer
Affiliation:
Massachusetts Institute of Technology
Get access Rights & Permissions [Opens in a new window]

Abstract

Two strategies for vaccine-delivery systems, both relying on concepts of controlled-release technology, are described in this review. The first strategy involves using biodegradable polymer microspheres for parenteral and oral delivery of antigens. The other strategy combines two technologies, the encapsulation of antigen within liposomes and liposome encapsulation in hydrogels, to protect them from a rapid degradation in vivo. Both strategies have shown promise in terms of increasing the immunogenicity of poorly immunogenic peptides and protein vaccines. The microencapsulation process, antigen stability, mechanism of antigen release, and optimal release kinetics for vaccine delivery are reviewed, and the strengths and weaknesses of each approach are discussed.

Type
Special Section: Vaccines and Public Health: Assessing Technologies and Public Policies
Information
International Journal of Technology Assessment in Health Care , Volume 10 , Issue 1 , Winter 1994 , pp. 121 - 130
Copyright
Copyright © Cambridge University Press 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Ada, G.Strategies for exploiting the immune system in the design of vaccines. Molecular Immunology, 1991, 28, 225–30.Google Scholar
2.Alonso, M. J., Cohen, S., Park, T. G., et al. Determinants of release rate of tetanus vaccine from polyester microspheres. Pharmaceutical Research, 1993, 10, 945–53.Google Scholar
3.Alving, C. R.Delivery of liposome-encapsulated drugs to macrophages. Pharmacological Therapy, 1983, 22, 407–24.CrossRefGoogle ScholarPubMed
4.Alving, C. R., Richards, R. L., & Moss, J.Effectiveness of liposomes as potential carriers for vaccines; application to cholera toxin and human malaria sporozoite antigen. Vaccine, 1986, 4, 166–72.Google Scholar
5.Cohen, S., Baño, M. C., Chow, M., et al. Alginate-lipid interactions can render changes in bilayer lipid permeability. Biochimica et Biophysica Acta, 1991, 1063, 95–102.Google Scholar
6.Cohen, S., Bernstein, H., Hewes, C., et al. The pharmacokinetics of, and humoral responses to, antigen delivered by microencapsulated liposomes. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 10440–44.Google Scholar
7.Cohen, S., Cochrane, A., Nardin, E., et al. Poly(lactic/glycolic acid) microspheres- immunization vehicles for synthetic peptide vaccines. Polymeric Materials Science and Engineering, 1992, 66, 91–92.Google Scholar
8.Cohen, S., Yoshioka, T., Lucarelli, M., et al. Controlled delivery systems for proteins based on poly (lactic/glycolic acid) microspheres. Pharmaceutical Research, 1991, 8, 713–20.Google Scholar
9.Davis, D., & Gregoriadis, G.Liposomes as adjuvants with immunopurified tetanus toxoid: Influence of liposomal characteristics. Immunology, 1987, 61, 229–34.Google Scholar
10.Eldridge, J. H., Gilley, R. M., Staas, J. K., et al. Biodegradable microspheres: Vaccine delivery system for oral administration. Current Topics in Microbiology and Immunology, 1989, 146, 59–66.Google Scholar
11.Eldridge, J. H., Hammond, C. J., Meulbroek, J. A., et al. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target Peyer's patches. Journal of Controlled Release, 1990, 11, 205–14.CrossRefGoogle Scholar
12.Eldridge, J. H., Meulbroek, J. A., Staas, J. K., et al. Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Advanced Experiments in Medicine and Biology, 1989, 251, 192–202.Google Scholar
13.Eldridge, J. H., Staas, J. K., Meulbroek, J. A., et al. Biodegradable and biocompatible poly (D, L-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhance the level of toxin-neutralizing antibodies. Infection and Immunity, 1991, 59, 2978–86.Google Scholar
14.Esparza, I., & Kissel, T.Parameters affecting the immunogenicity of microencapsulated tetanus toxoid. Vaccine, 1992, 10, 714–20.CrossRefGoogle ScholarPubMed
15.Freund, J.The mode of action of immunological adjuvants. Advances in Tuberculosis Research, 1956, 7, 130–48.Google Scholar
16.Gilding, D. K.Biodegradable polymers. Biocompatible Clinical Implantable Materials, 1981, 2, 209–32.Google Scholar
17.Gilding, D. K., & Reed, A. M.Biodegradable polymers for use in surgery polyglycolic-poly(lactic acid) homo and copolymers. Polymer, 1979, 11, 711–19.Google Scholar
18.Grant, J. P.The state of the world's children 1992. Oxford, UK. Oxford University Press, 1992.Google Scholar
19.Kohn, J., & Langer, R.Polymerization reactions involving the side chains of a-L-amino acids. Journal of the American Chemical Society, 1987, 109, 817–20.Google Scholar
20.Kohn, J., Niemi, S. M., Albert, E. C., et al. Single-step immunization using a controlled-release, biodegradable polymer with sustained adjuvant activity. Journal ofImmunolog-ical Methods, 1986, 95, 31–38.Google Scholar
21.Langer, R.New methods of drug delivery. Science, 1990, 249, 1527–33.Google Scholar
22.O'Hagan, D. T., Rahman, D., McGee, J. P., et al. Biodegradable microparticles as con-trolled-release antigen delivery systems. Immunology, 1991, 73, 239–42.Google Scholar
23.Preis, I., & Langer, R.A single-step immunization by sustained antigen release. Journal of Immunological Methods, 1979, 28, 193–97.CrossRefGoogle ScholarPubMed
24.Sanchez, Y., Ionescu-Matin, I., Dreesman, G. R., et al. Humoral and cellular immunity to hepatitis B virus-derived antigen: Comparative activity of Freund's complete adjuvant, alum and liposome. Infection and Immunity, 1980, 30, 728–33.Google Scholar
25.Schneider, A. K.Polylactide sutures. U.S. Patent, 1972, 3, 636–956.Google Scholar
26.Schreier, H., Levy, M., & Milhalko, P.Sustained release of liposome encapsulated genta-mycin and fate of phospholipid following intramuscular injection in mice. Journal of Controlled Release, 1987, 5, 187–92.Google Scholar
27.Singh, M., Singh, A., & Talwar, G. P.Controlled delivery of diphtheria toxoid using biodegradable poly(d.l-lactide) microcapsules. Pharmaceutical Research, 1991, 8, 958–61.Google Scholar
28.Wise, D. L., Fellman, T. D., Sanderson, J. E., et al. Lactic/glycolic acid polymers. In Gregoriadis, G. (ed.), Drug carriers in biology and medicine. London: Academic Press, 1979, 237–70.Google Scholar